ECSP22016180A - Proteínas de fusión terapéuticas - Google Patents

Proteínas de fusión terapéuticas

Info

Publication number
ECSP22016180A
ECSP22016180A ECSENADI202216180A ECDI202216180A ECSP22016180A EC SP22016180 A ECSP22016180 A EC SP22016180A EC SENADI202216180 A ECSENADI202216180 A EC SENADI202216180A EC DI202216180 A ECDI202216180 A EC DI202216180A EC SP22016180 A ECSP22016180 A EC SP22016180A
Authority
EC
Ecuador
Prior art keywords
fusion proteins
acute
therapeutic fusion
organ
tissue
Prior art date
Application number
ECSENADI202216180A
Other languages
English (en)
Inventor
Darko Skegro
Sebastien Irigaray
Karl Welzenbach
Marco Villani
Laurent Klein
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67875416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP22016180(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP22016180A publication Critical patent/ECSP22016180A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Signal Processing (AREA)

Abstract

La presente invención se refiere a proteínas de fusión adecuadas para su uso como medicamento o herramienta de investigación. Los usos terapéuticos de las proteínas de fusión pueden incluir la prevención o el tratamiento de trastornos inflamatorios agudos o crónicos y microvasculares y de órganos impulsados por el sistema inmunitario, por ejemplo, lesión renal aguda, síndrome de dificultad respiratoria aguda, sepsis, infarto agudo de miocardio, fibrosis tisular y otras lesiones de órganos resultantes del trauma tisular.
ECSENADI202216180A 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas ECSP22016180A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19196045 2019-09-06

Publications (1)

Publication Number Publication Date
ECSP22016180A true ECSP22016180A (es) 2022-04-29

Family

ID=67875416

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI202216180A ECSP22016180A (es) 2019-09-06 2022-03-03 Proteínas de fusión terapéuticas
ECSENADI202216558A ECSP22016558A (es) 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECSENADI202216558A ECSP22016558A (es) 2019-09-06 2022-03-04 Proteínas de fusión terapéuticas

Country Status (22)

Country Link
US (3) US20230220048A1 (es)
EP (3) EP4025239A1 (es)
JP (4) JP7671739B2 (es)
KR (3) KR20220058586A (es)
CN (8) CN114341194A (es)
AR (2) AR119905A1 (es)
AU (3) AU2020343512A1 (es)
BR (2) BR112022003745A2 (es)
CA (3) CA3152499A1 (es)
CO (2) CO2022002545A2 (es)
CR (2) CR20220089A (es)
CU (2) CU20220015A7 (es)
EC (2) ECSP22016180A (es)
IL (3) IL290618A (es)
JO (2) JOP20220058A1 (es)
MX (2) MX2022002638A (es)
MY (1) MY208682A (es)
PE (2) PE20220401A1 (es)
PH (2) PH12022550538A1 (es)
TW (2) TW202122414A (es)
WO (3) WO2021044360A1 (es)
ZA (2) ZA202201828B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7659499B2 (ja) * 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法
EP4326307A4 (en) * 2021-04-22 2025-03-05 Biolegend, Inc. PHOSPHATIDYLSERINE BINDING AGENT FOR THE DETECTION AND DEGRADATION OF PHOSPHATIDYLSERINE-POSITIVE CELLS
KR102801198B1 (ko) * 2021-06-28 2025-04-30 (주) 넥셀 특발성 폐섬유증 예방 또는 치료용 폴리펩타이드 및 이를 포함하는 약학 조성물
CN114288386B (zh) * 2022-01-25 2023-12-12 华中科技大学同济医学院附属协和医院 Del-1作为炎症性肠病新的生物标志物及治疗药物应用
TW202417520A (zh) * 2022-10-14 2024-05-01 南韓商伊米斯療法股份有限公司 融合分子和治療免疫性疾病的方法
WO2025086968A1 (zh) * 2023-10-25 2025-05-01 上海萨美细胞技术有限公司 一种用于治疗肺纤维化的药物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
AU2001261024A1 (en) 2000-04-12 2001-10-30 Delta Biotechnology Limited Albumin fusion proteins
FI117667B (fi) * 2001-07-05 2007-01-15 Univ Zuerich Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä
EP2277910A1 (en) 2001-12-21 2011-01-26 Human Genome Sciences, Inc. Albumin fusion proteins
CN101203234B (zh) 2005-05-13 2012-10-10 范斯坦医药研究院 乳脂小球表皮生长因子-因子ⅷ和脓毒病
CN101511866A (zh) * 2006-09-08 2009-08-19 Ambrx公司 经修饰的人类血浆多肽或Fc骨架和其用途
EP2215264B1 (en) * 2007-11-15 2015-04-01 The Feinstein Institute for Medical Research Prevention and treatment of inflammation and organ injury after ischemia/reperfusion using mfg-e8
JP2013509170A (ja) 2009-10-30 2013-03-14 ノボザイムス バイオファーマ デーコー アクティーゼルスカブ アルブミン変異体
ES2678144T3 (es) 2010-02-16 2018-08-09 Medimmune, Llc Composiciones relacionadas con SAH y métodos de uso
WO2011124718A1 (en) 2010-04-09 2011-10-13 Novozymes A/S Albumin derivatives and variants
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
CA2826142A1 (en) * 2011-02-03 2012-08-09 Xoma Technology Ltd. Methods and materials for enhancing functional protein expression in bacteria
US9045564B2 (en) 2011-02-15 2015-06-02 Medimmune, Llc HSA-related compositions and methods of use
JP2014510518A (ja) 2011-02-15 2014-05-01 メディミューン，エルエルシー Ｈｓａ関連組成物および使用方法
EP2701730A4 (en) * 2011-04-28 2015-05-27 The Feinstein Inst Medical Res MFG-E8 AND USES THEREOF
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
US20140302027A1 (en) * 2011-09-26 2014-10-09 University Of Louisville Research Foundation, Inc. Methods of treating periodontal inflammation and periodontal bone loss
RU2670063C2 (ru) 2012-11-08 2018-10-17 Альбумедикс А/С Варианты альбумина
EP2956002B1 (en) 2013-02-16 2017-09-06 Albumedix A/S Pharmacokinetic animal model
SG11201602289WA (en) 2013-08-23 2016-05-30 Riken Polypeptide exhibiting fluorescent properties, and utilization of same
SG11201608120TA (en) * 2014-03-31 2016-11-29 Hanmi Pharm Ind Co Ltd Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
WO2015150757A1 (en) * 2014-03-31 2015-10-08 British Telecommunications Public Limited Company Data communication
US20170136089A1 (en) * 2014-05-15 2017-05-18 The Trustees Of The University Of Pennsylvania Compositions and methods of regulating bone resorption
KR20170013621A (ko) 2015-07-28 2017-02-07 (주) 넥셀 Ｍｉｌｋ ｆａｔ ｇｌｏｂｕｌｅ－ＥＧＦ ｆａｃｔｏｒ（ＭＦＧ－Ｅ８）을 이용한 조직섬유화 예방 또는 치료용 조성물
CA3000742A1 (en) * 2015-10-02 2017-04-06 Silver Creek Pharmaceuticals, Inc. Bi-specific therapeutic proteins for tissue repair
JP7116736B2 (ja) * 2017-03-02 2022-08-10 ノバルティス アーゲー 操作されたヘテロ二量体タンパク質
US11028139B2 (en) 2017-05-17 2021-06-08 Nexel Co., Ltd. Recombinant protein for preventing or treating tissue fibrosis and composition for preventing or treating tissue fibrosis comprising the same
JP7659499B2 (ja) 2018-10-25 2025-04-09 ネクセル カンパニー，リミテッド 線維症を治療又は予防するための組成物及び方法

Also Published As

Publication number Publication date
EP4025238A1 (en) 2022-07-13
ZA202201827B (en) 2023-11-29
PE20221051A1 (es) 2022-06-30
AU2020340618A1 (en) 2022-04-07
PE20220401A1 (es) 2022-03-22
MY208682A (en) 2025-05-23
US20230265160A1 (en) 2023-08-24
CU20220015A7 (es) 2022-10-11
IL290660A (en) 2022-04-01
JP2022547111A (ja) 2022-11-10
CO2022002567A2 (es) 2022-04-08
CN118812727A (zh) 2024-10-22
CN118667031A (zh) 2024-09-20
AR119902A1 (es) 2022-01-19
CN114341195A (zh) 2022-04-12
CN114341195B (zh) 2025-04-25
JP2022547051A (ja) 2022-11-10
KR20220058585A (ko) 2022-05-09
MX2022002637A (es) 2022-03-25
JP2022547050A (ja) 2022-11-10
EP4025237A1 (en) 2022-07-13
CO2022002545A2 (es) 2022-04-08
JP7671739B2 (ja) 2025-05-02
CU20220016A7 (es) 2022-10-11
BR112022003762A2 (pt) 2022-05-31
US20230308835A1 (en) 2023-09-28
PH12022550539A1 (en) 2023-03-20
CN119285791A (zh) 2025-01-10
BR112022003745A2 (pt) 2022-05-31
IL290618A (en) 2022-04-01
AU2020343926A1 (en) 2022-04-07
US20230220048A1 (en) 2023-07-13
WO2021044360A1 (en) 2021-03-11
KR20220058586A (ko) 2022-05-09
EP4025239A1 (en) 2022-07-13
CR20220089A (es) 2022-03-30
JOP20220058A1 (ar) 2023-01-30
AU2020343512A1 (en) 2022-04-07
CN114341194A (zh) 2022-04-12
CA3152990A1 (en) 2021-03-11
ZA202201828B (en) 2023-10-25
CN118772293A (zh) 2024-10-15
CA3152500A1 (en) 2021-03-11
ECSP22016558A (es) 2022-04-29
PH12022550538A1 (en) 2023-03-20
AU2020340618B2 (en) 2025-01-23
CA3152499A1 (en) 2021-03-11
KR20220058588A (ko) 2022-05-09
MX2022002638A (es) 2022-03-25
CR20220096A (es) 2022-05-11
JP2025124629A (ja) 2025-08-26
AU2020343926B2 (en) 2024-11-21
CN114302896A (zh) 2022-04-08
TW202122415A (zh) 2021-06-16
TW202122414A (zh) 2021-06-16
TWI873177B (zh) 2025-02-21
CN118909136A (zh) 2024-11-08
AR119905A1 (es) 2022-01-19
WO2021044361A1 (en) 2021-03-11
JOP20220055A1 (ar) 2023-01-30
WO2021044362A1 (en) 2021-03-11
IL290675A (en) 2022-04-01

Similar Documents

Publication Publication Date Title
CO2022002545A2 (es) Proteínas de fusión terapéuticas
CY1124432T1 (el) Φαρμακευτικες συνθεσεις που αποτελουν ν-(3,5-διμεθοδυφαινυλ)-ν'-(1-μεθυλαιθυλ)-ν-[3-(1--μεθυλ-1η-πυραζολ-4-υλ)κινοοξαλιν-6-υλ]αιθανο-1,2-διαμινη
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
WO2015153959A3 (en) Small molecule inhibitors of mcl-1 and uses thereof
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
ECSP109889A (es) Composiciones terapeuticas y usos de las mismas
CN107406464A8 (zh) 精氨酸酶抑制剂及其治疗用途
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
MX2022003585A (es) Metodos para tratar hiperfenilalaninemia.
EA201791696A1 (ru) Композиция для лечения веноокклюзионной болезни печени
CU20210008A7 (es) Aspirasas solubilizadas
CL2017000117A1 (es) Dihidropirimidinonas bicíclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrófila.
CL2013000021A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo; procedimiento de preparacion; composiciones farmaceuticas que la contienen; y su uso par el tratamiento de las enfermedades cardiovasculares, tales como hipertension arterial, insuficiencia cardiaca o enfermedad coronaria estable.
BR112018068960A2 (pt) formulações de enalapril
CL2019002145A1 (es) Composición farmacéutica que comprende betahistina.
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
ES2537905B2 (es) Uso de 12- desoxiforboles para promover la proliferación de las células madre neurales
CL2017003465A1 (es) Uso combinado de bumetanida con ácido valproico o una de sus sales farmacéuticamente aceptables para restablecer la homeostasis de cl- y con ello, permitir la preparación de un fármaco efectivo en el tratamiento de la epilepsia, y especialmente, en el tratamiento de la epilepsia refractaria.
MX392735B (es) Uso de derivados de esteres de 1,4-di-n-oxido de quinoxalina para el tratamiento de la giardiasis como agentes anti-giardia-lamblia.